

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KRAUSS, et al.

Serial No.: Pending

Filed: Herewith

For: **PROSTAGLANDIN D₂
ANTAGONIST**

Examiner:

Group Art Unit:

Confirmation No.:

Irvine, California

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants provide with regard to the above-identified patent application entitled **PROSTAGLANDIN D₂ ANTAGONIST**, one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: February 12, 2004



Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:


Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date February 12, 2004 in an envelope as "Express Mail Post Office to Addressee" Mailing Label number **EV193721218US** addressed to Mail Stop: Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew

Name of person mailing paper



Signature of person signing paper

Date February 12, 2004

LIST OF ART CITED BY APPLICANT

| | |
|--|---|
| ATTY. DOCKET: 17373 CONCIPCONCIP (AP) | Serial No.: Pending |
| APPLICANTS: ACHIM M. KRAUSS, et al. | TITLE: PROSTAGLANDIN D ₂ ANTAGONIST |
| FILING DATE: Herewith | GROUP: |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NO. | DATE | NAME | CLASS | SUB-CLASS | FILING DATE (if applicable) |
|----------------------|----|-----------------|----------|---------------------|-------|-----------|--------------------------------|
| | AA | 2001/0051624A1 | 12/13/01 | Jones | | | 3/27/01 |
| | AB | 2003/0055077 A1 | 3/20/03 | Jones | | | 4/9/01 |
| | AC | 2003/0158246 A1 | 8/21/03 | Berthelette, et al. | | | 1/21/03 |
| | AD | 5,491,254 | 2/13/96 | Sato, et al. | | | |
| | AE | 4,808,608 | 2/28/89 | Guindon, et al. | | | |
| | AF | 6,369,082 B1 | 4/9/02 | Lacombe, et al. | | | |
| | AG | 6,369,089 B1 | 4/9/02 | Burk, et al. | | | |
| | AH | 6,410,583 B1 | 6/25/02 | Labelle, et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION (yes/no) |
|--|----|-----------------|----------|---------|-------|-----------|-------------------------|
| | BA | EPO 837 0512 A1 | 22.04.98 | EPO | | | Y |
| | BB | WO 98/25919 | 18.06.98 | PCT | | | Y |
| | BC | WO 99/62555 | 09.12.99 | PCT | | | N |
| | BD | | | | | | |

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|--|----|--|
| | CA | Boie, Y, et al., "Molecular cloning and characterization of the human prostanoid DP receptor" <i>Journal of Biological Chemistry</i> , Vol. 270, No. 32, August 11 1995, pp 18910-18916 |
| | CB | Breyer, M.D., et al., "Functional and molecular aspects of renal prostaglandin receptors" <i>J. Am. Soc. Nephrol.</i> , 1996;7:8-17 |
| | CC | Coleman, R.A., "Prostanoid Receptors" <i>Eicosanoids From Biotechnology to Therapeutic Applications</i> , Plenum Press, 1996, Chp. 14, 137-154 |
| | CD | Darius, H., et al., Inhibition of human platelets and polymorphonuclear neutrophils by the otent and metabolically stable prostaglandin D2 analog ZK 118.182" <i>Europoean Journal of Pharm</i> , 258(1994) 207-213 |
| | CE | Giles, H., et al., The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel selective and potent competitive antagonist", <i>Br. J. Pharmacol.</i> , (1989), 96, 291-300 |
| | CF | Hirai, H, et al., "Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2", <i>J. Exp. Med, The Rockefeller Univ. Press</i> , Vol. 192, No. 2, Jan. 15 2001, 255-261, |
| | CG | Ichikawa, A., "Molecular aspects of the structures and functions of the prostaglandin E receptors", <i>J of Lipid Mediators and Cell Signalling</i> , 14 (1996) 83-87 |

EXAMINER _____ **DATE CONSIDERED** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

| | |
|--|---|
| ATTY. DOCKET: 17373 CONCIPCONCIP (AP) | Serial No.: Pending |
| APPLICANTS: ACHIM M. KRAUSS, et al. | TITLE: PROSTAGLANDIN D ₂ ANTAGONIST |
| FILING DATE: Herewith | GROUP: |

| | | |
|--|----|--|
| | CH | Matsuoka, T., et al., "Prostaglandin D2 as a Mediator of allergic asthma", <i>Science</i> Vol. 287, 17 March 2000, pp. 2013-2017 |
| | CI | Negishi, M. et al., "Prostanoid receptors and their biological actions" <i>Prog. Lipid Res.</i> Vol. 32, No. 4, pp 417-434 1993 |
| | CJ | Ney, P., et al., "GD 2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils", <i>Eicosanoids</i> 1991 4:21-28 |
| | CK | Pons, F., et al., "Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue ZK.182" <i>European Journal of Pharm</i> , 261 (1994) 237-247 |
| | CL | Rangachari, P.K., et al., "Effects of a selective DP receptor agonist (BW 245C) and antagonists (BW A868C) on the canine colonic epithelium : an argument for a different DP receptor", <i>The Journal of Pharmacology and experimental therapeutics</i> , Vol. 275, No. 2, 611-617 (1995) |
| | CM | Tsuri, T., et al, "Bicyclo [2.2.1]heptane and 6,6-dimethylbicyclo[3.1.1]heptane Derivatives: orally active, potent and selective prostaglandin D2 receptor antagonists" <i>J. Med. Chem</i> , 1997, 40, 3504-3507 |
| | CN | Wright, D.H., et al., "A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor", <i>European Journal of Pharmacology</i> , 377 (1999) 101-115 |
| | CO | Wright, D.H., et al., "Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist", <i>British J. of Pharm.</i> (1998) 123,1317-1324 |

EXAMINER _____ **DATE CONSIDERED** _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.